Anticancer Acridone-1,2,4-Triazines as Inhibitors of NF-κB Suppression Activity, Promoting Lifespan Extension in Mice with Oncology

Journal of Analytical Science and Technology · Springer Nature · 2026-09-01 · DOI: 10.1134/S1990750826600603

Аннотация

Abstract Nuclear factor kappa‑B (NF‑κB) orchestrates cellular stress responses, with its dysregulation driving numerous pathologies. While NF‑κB hyperactivation is extensively characterized, the pathological consequences of excessive suppression—mediated by hyperactive endogenous negative regulators—represent an emerging therapeutic frontier. Here, we report the first evaluation of two acridone‑1,2,4‑triazine derivatives ( 7a and 7e ) as inhibitors of excessive NF‑κB suppression and investigate their impact on lifespan in tumor‑bearing mice. In Ercc1 ‑deficient senescent murine embryonic fibroblasts, 7a and 7e reduced senescence‑associated β‑galactosidase‑positive cells by >50%, suppressed proinflammatory SASP markers (TNF‑α, MCP‑1) by ~48–51%, and upregulated the cell cycle inhibitor p27 (1.5–2.1 fold). In aged (>2 years) wild‑type mice with histologically confirmed late‑stage malignancies, intraperitoneal administration (10 mg/kg, thrice weekly for 15 weeks) produced remarkable outcomes: 52% reduction in tumor burden at 7 weeks, significant muscle tissue regeneration, and reduction of the composite “aging index” from 4 to 2. These findings establish acridone‑1,2,4‑triazines as a promising pharmacological class operating through a mechanistically distinct paradigm—targeting hyperactive NF‑κB suppressors rather than NF‑κB itself—with broad therapeutic implications for geriatric oncology and age‑associated pathologies.

Читать у издателя →

Похожие статьи